Tồn tại lâu dài ở bệnh nhân glioblastoma tái phát được điều trị bằng bevacizumab: một nghiên cứu hồi cứu đa trung tâm

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996 Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610–622 Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622 Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708 Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722 Wong ET, Gautam S, Malchow C et al (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Cancer Netw JNCCN 9(4):403–407 Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963 Lombardi G, Pambuku A, Bellu L et al (2017) Effectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 111:94–102 Schaub C, Tichy J, Schäfer N et al (2016) Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol 129(1):93–100 Bi WL, Beroukhim R (2014) Beating the odds: extreme long-term survival with glioblastoma. Neuro-Oncol 16(9):1159–1160 Gately L, McLachlan S-A, Philip J et al (2018) Long-term survivors of glioblastoma: a closer look. J Neurooncol 136(1):155–162 Johnson DR, Omuro AMP, Ravelo A et al (2018) Overall survival in patients with glioblastoma before and after bevacizumab approval. Curr Med Res Opin 34(5):813–820 Chen C, Ravelo A, Yu E et al (2015) Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. J Neurooncol 122(3):595–605 Gramatzki D, Roth P, Rushing EJ et al (2018) Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdy106 Bronnimann C, Izquierdo C, Cartalat S et al (2018) Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. J Neurooncol. https://doi.org/10.1007/s11060-018-2780-1 Balaña C, Estival A, Pineda E et al (2017) Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neuro-Oncol Pract 4(1):15–23 Hertenstein A, Hielscher T, Menn O et al (2016) Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. J Neurooncol 129(3):533–539 Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro-Oncol 16(6):823–828 Reardon DA, Herndon JE, Peters KB et al (2012) Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer 107(9):1481–1487 Hamza MA, Mandel JJ, Conrad CA et al (2014) Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135–140 Piccioni DE, Selfridge J, Mody RR et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncol 16(6):815–822 Wiestler B, Radbruch A, Osswald M et al (2014) Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. J Neurooncol 117(1):85–92 Franceschi E, Lamberti G, Paccapelo A et al (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol 20:18. https://doi.org/10.1007/s11060-018-2873-x Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28(11):1963–1972 Ellingson BM, Chung C, Pope WB et al (2017) Pseudoprogression, radionecrosis, inflammation or true tumor progression? Challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol 134(3):495–504 Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495 Duerinck J, Clement PM, Bouttens F et al (2015) Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol 262(3):742–751 Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113(11):1642 Flieger M, Ganswindt U, Schwarz SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117(2):337–345 Palmer JD, Bhamidipati D, Song A et al (2018) Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? J Neurooncol 140(3):623–628 Brandes AA, Bartolotti M, Tosoni A et al (2015) Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20(2):166–175 Vredenburgh JJ, Cloughesy T, Samant M et al (2010) Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 15(12):1329–1334 Taphoorn MJB, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 33(19):2166–2175 Dirven L, van den Bent MJ, Bottomley A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer Oxf Engl 1990 51(10):1321–1330 Chen C, Huang R, MacLean A et al (2013) Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol 115(2):267–276 Lv S, Teugels E, Sadones J et al (2011) Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res 31(12):4457–4463 Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y et al (2016) Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial. Cancer Res 76(3):525–534 Gerber NK, Goenka A, Turcan S et al (2014) Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncol 16(9):1186–1195 Amelot A, De Cremoux P, Quillien V et al (2015) IDH-Mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS ONE 10(7):e0130596 Hartmann C, Hentschel B, Simon M et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19(18):5146–5157 Levin VA, Mendelssohn ND, Chan J et al (2015) Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. J Neurooncol 122(1):145–150 Lorgis V, Maura G, Coppa G et al (2012) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 107(2):351–358 Ajlan A, Thomas P, Albakr A et al (2017) Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 135(1):99–105 Batchelor TT, Gerstner ER, Emblem KE et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064